New Ray Medicine International Holding Limited (HKG:6108)

Market Cap	47.14M
Revenue (ttm)	121.93M +240.0%
Net Income	-34.38M
EPS	-0.21
Shares Out	200.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	914,080
Average Volume	283,360
Open	0.2500
Previous Close	0.2490
Day's Range	0.2300 - 0.2500
52-Week Range	0.2340 - 0.6100
Beta	-4.62
RSI	37.08
Earnings Date	Mar 25, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor rel...

• Industry: Pharmaceutical Retailers
• Sector: Healthcare
• Founded: 2001
• Employees: 30
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6108

Financial Performance

In 2024, HKG:6108's revenue was 93.95 million, an increase of 87.31% compared to the previous year's 50.15 million. Losses were -31.01 million, 39.9% more than in 2023.